AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 188 filers reported holding AKERO THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.90 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,187,534 | +16.1% | 43,249 | +7.1% | 0.00% | 0.0% |
Q2 2023 | $1,884,595 | +67.6% | 40,364 | +37.4% | 0.00% | – |
Q1 2023 | $1,124,347 | +55.1% | 29,387 | +122.1% | 0.00% | – |
Q4 2022 | $724,948 | +107.7% | 13,229 | +29.2% | 0.00% | – |
Q3 2022 | $349,000 | +391.5% | 10,236 | +36.9% | 0.00% | – |
Q2 2022 | $71,000 | -27.6% | 7,478 | +8.2% | 0.00% | – |
Q1 2022 | $98,000 | -32.9% | 6,909 | 0.0% | 0.00% | – |
Q4 2021 | $146,000 | -4.6% | 6,909 | +0.6% | 0.00% | – |
Q3 2021 | $153,000 | +64.5% | 6,867 | +81.7% | 0.00% | – |
Q2 2021 | $93,000 | +34.8% | 3,779 | +60.3% | 0.00% | – |
Q1 2021 | $69,000 | +9.5% | 2,358 | -3.0% | 0.00% | – |
Q4 2020 | $63,000 | -16.0% | 2,430 | 0.0% | 0.00% | – |
Q3 2020 | $75,000 | +63.0% | 2,430 | +31.8% | 0.00% | – |
Q2 2020 | $46,000 | +70.4% | 1,844 | +44.1% | 0.00% | – |
Q1 2020 | $27,000 | +35.0% | 1,280 | +40.7% | 0.00% | – |
Q4 2019 | $20,000 | +17.6% | 910 | +19.9% | 0.00% | – |
Q3 2019 | $17,000 | – | 759 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ATP Life Science Ventures, L.P. | 5,830,203 | $169,134,000 | 18.83% |
venBio Partners LLC | 2,444,311 | $70,909,000 | 6.74% |
Versant Venture Management, LLC | 617,727 | $17,920,000 | 3.49% |
Redmile Group, LLC | 2,513,746 | $72,924,000 | 1.03% |
Boxer Capital, LLC | 831,495 | $24,122,000 | 0.82% |
Integral Health Asset Management, LLC | 85,000 | $2,466,000 | 0.70% |
Vivo Capital, LLC | 673,280 | $19,532,000 | 0.69% |
SILVERARC CAPITAL MANAGEMENT, LLC | 32,000 | $928,000 | 0.51% |
Cormorant Asset Management, LP | 742,549 | $21,541,000 | 0.48% |
HHLR ADVISORS, LTD. | 1,656,673 | $48,060,000 | 0.48% |